TICKERNOMICS Sign up
Last Update: 2024-12-27 15:30:48
Appili Therapeutics Inc ( APLI.TO ) https://www.appilitherapeutics.com
0.02USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
Canada
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
-19.40%
APLI.TO
SPY
32.66%
-74.53%
APLI.TO
SPY
108.59%
-95.76%
APLI.TO
SPY
302.52%
APLI.TO
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
2.95
10.08
0.01
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-1.03
3.42
-0.33
-60.71
0.00
-1.26
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-23261.48
-28.11
-22582.97
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
8.8096
1220.80
937.53
1.22
Other Earnings and Cash Flow Stats:
Appili Therapeutics Inc ( APLI.TO ) Net Income TTM ($MM) is -2.85
Appili Therapeutics Inc ( APLI.TO ) Operating Income TTM ($MM) is -4.08
Appili Therapeutics Inc ( APLI.TO ) Owners' Earnings Annual ($MM) is -1.91
Appili Therapeutics Inc ( APLI.TO ) Current Price to Owners' Earnings ratio is -1.63
Appili Therapeutics Inc ( APLI.TO ) EBITDA TTM ($MM) is -4.07
Appili Therapeutics Inc ( APLI.TO ) EBITDA Margin is -22582.97%
Capital Allocation:
Appili Therapeutics Inc ( APLI.TO ) has paid 0.00 dividends per share and bought back 0.0 million shares in the past 12 months
Appili Therapeutics Inc ( APLI.TO ) has increased its debt by 1.424932839695 million USD in the last 12 months
Capital Structure:
Appili Therapeutics Inc ( APLI.TO ) Interest-bearing Debt ($MM) as of last quarter is 7
Appili Therapeutics Inc ( APLI.TO ) Annual Working Capital Investments ($MM) are 0
Appili Therapeutics Inc ( APLI.TO ) Book Value ($MM) as of last quarter is -10
Appili Therapeutics Inc ( APLI.TO ) Debt/Capital as of last quarter is -82%
Other Balance Sheet Stats:
Appili Therapeutics Inc ( APLI.TO ) has 0 million in cash on hand as of last quarter
Appili Therapeutics Inc ( APLI.TO ) has 10 million of liabilities due within 12 months, and long term debt 7 as of last quarter
Appili Therapeutics Inc ( APLI.TO ) has 121 common shares outstanding as of last quarter
Appili Therapeutics Inc ( APLI.TO ) has 0 million USD of preferred stock value
Academic Scores:
Appili Therapeutics Inc ( APLI.TO ) Altman Z-Score is -66.51 as of last quarter
Appili Therapeutics Inc ( APLI.TO ) Piotroski Score is 1.00 as of last quarter
Corporate Governance:
Appili Therapeutics Inc ( APLI.TO ) largest shareholder is owning shares at 0.00 ($MM) value
(an insider) shares of Appili Therapeutics Inc ( APLI.TO ) for the amount of $ on
0.05% of Appili Therapeutics Inc ( APLI.TO ) is held by insiders, and 8.66% is held by institutions
Appili Therapeutics Inc ( APLI.TO ) went public on 1970-01-01
Other Appili Therapeutics Inc ( APLI.TO ) financial metrics:
FCF:-0.49
Unlevered Free Cash Flow:-4.88
EPS:-0.04
Operating Margin:-23261.48
Gross Profit Margin:-28.11
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:51.72
Beta:1.22
Buffet's Owners Earnings:-1.91
Price to Owner's Earnings:-1.63
About Appili Therapeutics Inc ( APLI.TO ) :
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes Favipiravir for pandemic influenza and COVID-19; ATI-2307, an antifungal candidate, which is in clinical stage for the treatment of cryptococcal meningitis and invasive candidiasis; ATI-1503 that develops a class of gram-negative targeting antibiotics; ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis. The company has a strategic alliance with AiPharma Global Holdings LLC for the development of Avigan/Reeqonus (favipiravir). Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.